MCM
GNMK

Moore Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History

Moore Capital Management’s Portfolio GNMK Stock Details GNMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-150,000
Closed -$729K – 345
2018
Q4 		$729K Buy
+150,000
New +$781K 0.03% 180

Other funds holding GNMK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Moore Capital Management's GNMK Position: Q1 2019 in Review

Moore Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q1 2019, closing a stake of 150,000 shares — an estimated $729K sold.

Moore Capital Management first reported a position in GNMK in Q4 2018 and held it in 1 quarter. The position peaked at $729K in Q4 2018. 106 funds tracked by Wall St. Rank hold GNMK as of Q1 2019.

  • Moore Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q1 2019 after selling out during the quarter.
  • Moore Capital Management sold 150,000 GenMark Diagnostics, Inc shares in Q1 2019, an estimated $729K.
  • Moore Capital Management first reported a position in GenMark Diagnostics, Inc in Q4 2018 and held it in 1 quarter.
  • Moore Capital Management's GenMark Diagnostics, Inc position peaked at $729K in Q4 2018.
  • 106 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q1 2019.

Based on Moore Capital Management's 13F filing for Q1 2019, filed 15 May 2019.